The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH -wild type and -mutant lower grade gliomas
Der IDH-Paradox: Metaanalyse der alkylierenden Chemotherapie bei IDH-Wildtyp- und IDH-mutierten niedriggradigen Gliomen
Neuro-Oncology · 03.10.2024 · 26 (10) · 1839-1849
DOI: 10.1093/neuonc/noae102 ↗Auf einen Blick
Eine Metaanalyse von 6 Studien zeigte bei IDH-mutierten Gliomen Vorteile durch alkylierende Chemotherapie zusätzlich zur Radiotherapie. Bei IDH-Wildtyp-Tumoren verbesserte sich nur das PFS, nicht das OS.
Fragestellung
Welchen Effekt hat alkylierende Chemotherapie zusätzlich zur Radiotherapie bei WHO-Grad-2- bis -3-Gliomen mit IDH-Wildtyp- oder IDH-Mutation?
Methode
Metaanalyse randomisierter klinischer Studien zu WHO-Grad-2- bis -3-Gliomen ab 2009; Vergleich alkylierende Chemoradiotherapie vs. Radiotherapie allein; Random-effects-Modell mit inverse-variance pooling.
Ergebnisse
6 Studien mit 1204 Patient:innen (430 IDH-wt, 774 IDH-mutant). IDH-wt: PFS besser (HR 0,77; 95 %-KI 0,62–0,97), OS nicht signifikant (HR 0,87; 95 %-KI 0,64–1,18). IDH-mutant: OS (HR 0,52; 95 %-KI 0,42–0,64) und PFS (HR 0,47; 95 %-KI 0,39–0,57) besser.
Schlussfolgerung der Autor:innen
Alkylierende Chemotherapie senkt bei IDH-mutierten Gliomen Mortalität und Progression. Für IDH-Wildtyp-diffuse niedriggradige Gliome bleibt das optimale Management unklar, da es wenig Evidenz für einen OS-Vorteil gibt.
Kernaussagen
- IDH-mutant: besseres OS und PFS unter alkylierender Chemotherapie
- IDH-wt: PFS verbessert, OS nicht signifikant
- 6 randomisierte Studien mit 1204 Patient:innen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Neuro-Oncology, online erschienen am 29.06.2024. Verfasst von Connor J Kinslow und 16 weiteren Autor:innen. Beteiligte Einrichtung: Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, New Yo…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Alkylating, Brain Neoplasms, Glioma, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
IDH-wild type (-wt) status is a prerequisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low-grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas, irrespective of grade, the benefit for IDH-wt diffuse histologic lower-grade gliomas is unclear.
Methods
We performed a meta-analysis of randomized clinical trials for World Health Organization (WHO) grades 2–3 gliomas (2009 to present) to determine the effect of alkylating chemotherapy on IDH-wt and -mutant gliomas using a random-effects model with inverse-variance pooling.
Results
We identified 6 trials with 1204 patients (430 IDH-wt, 774 IDH-mutant) that evaluated alkylating chemoradiotherapy versus radiotherapy alone, allowing us to perform an analysis focused on the value of adding alkylating chemotherapy to radiotherapy. For patients with IDH-wt tumors, alkylating chemotherapy added to radiotherapy was associated with improved PFS (HR:0.77 [95% CI: 0.62–0.97], P = .03) but not OS (HR:0.87 [95% CI: 0.64–1.18], P = .17). For patients with IDH-mutant tumors, alkylating chemotherapy added to radiotherapy improved both OS (HR:0.52 [95% CI: 0.42–0.64], P < .001) and PFS (HR = 0.47 [95% CI: 0.39–0.57], P < .001) compared to radiotherapy alone. The magnitude of benefit was similar for IDH-mutant gliomas with or without 1p19q-codeletion.
Conclusions
Alkylating chemotherapy reduces mortality by 48% and progression by 53% for patients with IDH-mutant gliomas. Optimal management of IDH-wt diffuse histologic lower-grade gliomas remains to be determined, as there is little evidence supporting an OS benefit from alkylating chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, New York, USA.
- Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, New York, USA.
- Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, New York, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Departments of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York, New York, USA.
ORCID-Profile: Connor J Kinslow, Jeffrey N Bruce, Tony J C Wang
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Kinslow, C. J., Roy, S., Iwamoto, F. M., Brown, P. D., DeStephano, D. M., Canoll, P. D., Qureshi, S. S., Gallito, M., Sisti, M. B., Bruce, J. N., Horowitz, D. P., Kachnic, L. A., Neugut, A. I., Yu, J. B., Mehta, M. P., Cheng, S. K., & Wang, T. J. C. (2024). The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH -wild type and -mutant lower grade gliomas. Neuro-Oncology, 26(10), 1839-1849. https://doi.org/10.1093/neuonc/noae102
Vancouver
Kinslow CJ, Roy S, Iwamoto FM, Brown PD, DeStephano DM, Canoll PD, et al. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH -wild type and -mutant lower grade gliomas. Neuro-Oncology. 2024;26(10):1839-1849. doi:10.1093/neuonc/noae102
BibTeX
@article{Kinslow2024,
author = {Kinslow, Connor J and Roy, Soumyajit and Iwamoto, Fabio M and Brown, Paul D and DeStephano, David M and Canoll, Peter D and Qureshi, Summer S and Gallito, Matthew and Sisti, Michael B and Bruce, Jeffrey N and Horowitz, David P and Kachnic, Lisa A and Neugut, Alfred I and Yu, James B and Mehta, Minesh P and Cheng, Simon K and Wang, Tony J C},
title = {The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH -wild type and -mutant lower grade gliomas},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {10},
pages = {1839--1849},
doi = {10.1093/neuonc/noae102}
}
EUVIMED